ILMN stock forecast, quote, news & analysis
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications... Show more
Illumina (ILMN) Stock Analysis: AI and Clinical Momentum Face a Valuation Reality Check
Key Takeaways
- Illumina shares have climbed roughly 95% year-to-date, outpacing both the broader life-sciences sector and the S&P 500 as investors reframe its sequencing platforms as infrastructure for AI-driven clinical workloads.
- Over the most recent 30-day stretch, the stock has been essentially flat, consolidating after an early-October intraday spike toward $309 before settling back near $269.
- Second-quarter 2026 revenue rose 9.5% year over year to $1.16 billion, and management raised its full-year revenue and adjusted EPS guidance.
- NovaSeq X adoption remains the core growth engine, with more than 95 placements in the second quarter and the majority of high-throughput sequencing volume now transitioned to the platform.
- Clinical markets represent roughly 65% of sequencing consumables revenue, while regulatory and demand uncertainty in China continues to weigh on results.
- Analyst sentiment has been mixed on valuation: UBS upgraded the stock to Buy in September, while Stephens downgraded it to Equal Weight in late October.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages.
- Discover how AI-powered strategies are scanning this and thousands of other tickers on the Trending AI Robots page.
Current Market Snapshot
Illumina has been one of the more notable momentum stories in life sciences over the past year, gaining roughly 95% year-to-date and setting fresh 52-week highs in early October. Much of that advance reflects a fundamental re-rating of the company: investors have increasingly positioned its gene-sequencing technology as foundational infrastructure for artificial intelligence applications and for sequencing-intensive clinical diagnostics.
Over the trailing 30 days, however, the rally has paused. After touching an intraday high near $309, shares pulled back to the mid-to-high $260s and closed near $269, leaving the stock effectively unchanged versus a month earlier. The pullback has coincided with analyst caution on valuation following the strong year-to-date run, underscoring that sentiment around the name is now more balanced between growth optimism and price discipline.
Illumina (ILMN) Business Overview and Competitive Position
Headquartered in San Diego, California, Illumina develops sequencing- and array-based systems used to analyze genetic variation and biological function. Its products serve life-sciences research, oncology, reproductive health, agriculture, and other emerging applications, with customers spanning academic research centers, hospitals, government laboratories, and pharmaceutical, biotechnology, and diagnostic companies.
Following the June 2024 spin-off of GRAIL, the company has sharpened its focus on three pillars: its core sequencing franchise, an expanding multiomics portfolio, and growing services, data, and software offerings. Illumina's competitive strength rests on its installed base, its high-throughput NovaSeq X platform, and a razor-and-blade model in which instrument placements drive recurring consumables revenue. The company's expansion into proteomics through its acquisition of SomaLogic in early 2026 extends that franchise beyond DNA sequencing.
Recent Developments Driving ILMN
Several verified developments have shaped the stock over the past month. On the earnings front, Illumina's July 30 second-quarter report showed revenue of $1.16 billion, up 9.5% year over year, with non-GAAP EPS of $1.31 and better-than-guided margins. Management raised full-year 2026 revenue guidance to $4.60–$4.64 billion and adjusted EPS guidance to $5.30–$5.40, while reiterating its path toward high-single-digit revenue growth in 2027.
Operationally, NovaSeq X placements exceeded 95 units in the second quarter, with roughly 83% of high-throughput volumes and 59% of revenues already transitioned to the platform. Clinical markets accounted for approximately 65% of sequencing consumables revenue, reflecting broader adoption of next-generation sequencing-based diagnostics and whole-genome sequencing.
Analyst activity has been mixed. UBS upgraded Illumina to Buy from Neutral in September, and Argus Research maintained a Buy rating, while Bernstein reiterated a Hold with a $215 price target. In late October, Stephens downgraded the stock to Equal Weight from Overweight with a $275 price target, citing premium valuations and more balanced risk-reward after the stock's sharp year-to-date advance.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a much larger universe of AI-powered bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots surface in this featured section. The bots differ meaningfully in approach, holding timeframe, and performance metrics, allowing traders to browse strategies aligned with their own risk preferences and objectives. The page is designed as a discovery tool for those interested in data-driven, rules-based trading, offering a practical way to explore how automation is being applied across equity markets.
2026 Outlook and What Investors Should Watch
Looking ahead, investors are likely to focus on several forward-looking drivers. The next earnings report, expected around late October, will be closely watched against management's third-quarter guidance for revenue of $1.14–$1.16 billion and non-GAAP EPS of $1.33–$1.38, along with any update to full-year targets. Continued NovaSeq X placement momentum and the pace of the installed base's transition to the platform remain central to the consumables pull-through story that underpins 2027 growth expectations.
Key risks include ongoing regulatory and demand uncertainty in Greater China, where revenues have declined sharply, as well as cost pressures tied to tariffs, freight, and component inflation. Competitive dynamics in high- and mid-throughput sequencing, research-funding softness, and valuation levels after a near-doubling of the share price are additional factors that could influence the stock's next move. These considerations are presented for context and do not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for ILMN shows an upward move is likely
ILMN's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 214 similar instances where the Aroon Indicator showed a similar pattern. In 178 of the 214 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 58 cases where ILMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ILMN as a result. In 73 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +3.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 203 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for ILMN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 19 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
ILMN broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.870) is normal, around the industry mean (65.632). P/E Ratio (51.850) is within average values for comparable stocks, (1.899). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties